Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach

In severe asthma with type 2 (T2) inflammation, biologics targeting key mediators of T2 inflammation, including interleukin (IL)-5, IL-4/IL-13, and immunoglobulin (Ig)E, remarkably improve the management of severe asthma, providing new insights into the clinical course of asthma such as disease modi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamada, Kazuki, Oishi, Keiji, Murata, Yoriyuki, Hirano, Tsunahiko, Matsunaga, Kazuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665775/
https://www.ncbi.nlm.nih.gov/pubmed/34908847
http://dx.doi.org/10.2147/JAA.S340684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665775/
https://www.ncbi.nlm.nih.gov/pubmed/34908847
http://dx.doi.org/10.2147/JAA.S340684

Ejemplares similares